Therapeutic Areas

Metabolics

Type 2 Diabetes »

Among the many classes of effective treatments for type 2 diabetes, a new class called incretin mimetics represents some very important advantages. Incretin mimetics have the effect of lowering blood glucose and decreasing weight through multiple biological activities. The development of incretin mimetics offering these beneficial effects has been an important focus of research in the fields of type 2 diabetes and obesity. The first incretin mimetic was approved by the US FDA in 2005 and others are currently in clinical and preclinical development.

Obesity »

Intarcia is evaluating a series of human peptides for delivery with the DUROS technology as potential treatments for obesity. Based on the success Intarcia has achieved with human interferon and exenatide, we believe we can maintain stability and continuously deliver consistent levels of such peptides with the DUROS technology addressing some of the primary obstacles to developing safe and effective therapies in this class.

 

Hepatitis C »

Intarcia is developing interferon for delivery from the DUROS® device to improve the treatment of HCV by offering a more convenient therapy that may improve long term outcomes. The current standard of care for hepatitis C is a combination of pegylated alpha interferon and ribavirin. Standard therapy fails to induce sustained response in a majority of patients and the 48-week course of weekly injections required for most patients causes frequent and at times severe side effects. Such side effects may discourage patient compliance to therapy leading to dose reduction and at times treatment discontinuation.